Details for New Drug Application (NDA): 212627
✉ Email this page to a colleague
The generic ingredient in NEOSTIGMINE METHYLSULFATE is neostigmine methylsulfate. There are nine drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.
Summary for 212627
Tradename: | NEOSTIGMINE METHYLSULFATE |
Applicant: | Umedica |
Ingredient: | neostigmine methylsulfate |
Patents: | 0 |
Pharmacology for NDA: 212627
Mechanism of Action | Cholinesterase Inhibitors |
Medical Subject Heading (MeSH) Categories for 212627
Suppliers and Packaging for NDA: 212627
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 212627 | ANDA | Nivagen Pharmaceuticals, Inc. | 75834-149 | 75834-149-10 | 10 CARTON in 1 PACKAGE (75834-149-10) / 1 VIAL, MULTI-DOSE in 1 CARTON (75834-149-01) / 10 mL in 1 VIAL, MULTI-DOSE |
NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 212627 | ANDA | Nivagen Pharmaceuticals, Inc. | 75834-150 | 75834-150-10 | 10 CARTON in 1 PACKAGE (75834-150-10) / 1 VIAL, MULTI-DOSE in 1 CARTON (75834-150-01) / 10 mL in 1 VIAL, MULTI-DOSE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 5MG/10ML (0.5MG/ML) | ||||
Approval Date: | Nov 3, 2022 | TE: | AP | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 10MG/10ML (1MG/ML) | ||||
Approval Date: | Nov 3, 2022 | TE: | AP | RLD: | No |
Complete Access Available with Subscription